Eric Sagonowsky is a Senior Editor for the Fierce life sciences group, with a focus on the pharmaceutical industry. He writes for Fierce Pharma and his work has also appeared in Biotech. Eric covers a wide range of topics including drug approvals, regulatory updates, market trends, and financial developments in the pharmaceutical industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Eric Sagonowsky's articles predominantly cover announcements from the healthcare and pharmaceutical sectors, with a focus on FDA approvals, drug companies, medical research, and broader healthcare topics. His coverage suggests he would likely be interested in receiving pitches related to new drug approvals, clinical trial results or significant developments within pharmaceutical companies.
Given his extensive press release coverage (28%), Eric is likely open to receiving news directly from pharmaceutical companies about their latest products and milestones. Additionally, given the emphasis on government announcements (16%), he might also be interested in regulatory changes impacting the industry.
Since there is no specified geographic focus for Eric's coverage area, it can be inferred that he covers global developments within the pharmaceutical and healthcare industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Eric Sagonowsky
In recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through its
By: Eric Sagonowsky
AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual meeting, a cancer antibody from Akeso and Summit Therapeutics stole the show. More Chinese biopharma players are coming under scrutiny from U.S. lawmakers. Plus more.
By: Eric Sagonowsky
About a month after Eisai initiated a rolling FDA application for its subcutaneous form of Leqembi, the U.S. agency has accepted the filing.
By: Angus Liu, Eric Sagonowsky, Zoey Becker, Kevin Dunleavy, Fraiser Kansteiner
After a period of leadership transition for many of the world's top drugmakers in recent years, the industry's CEO pay rankings appear to be returning to a state of equilibrium.
By: Eric Sagonowsky
Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court.
By: Eric Sagonowsky
In recent months, frequent pharma critic Sen.
By: Eric Sagonowsky
As the process surrounding Medicare's drug price negotiations rolls on this summer—and as the pharmaceutical industry continues to loudly voice its complaints—another lawsuit contesting the legal viability of the setup has come up short.
By: Ayla Ellison, Fraiser Kansteiner, Eric Sagonowsky
Pharmaceutical CEOs often earn pay packages worth tens of millions of dollars for leading the top drugmaking companies in the industry.
By: Eric Sagonowsky
Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach.
By: Eric Sagonowsky
While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of new medicines and proposed label expansions.
(833) 317-6278 
